Aging, Geriatric Syndromes and Clonal Hematopoiesis

Sponsor
Washington University School of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT02604563
Collaborator
Edward P. Evans Foundation (Other)
2,000
1
169.7
11.8

Study Details

Study Description

Brief Summary

In this study the investigators will incorporate a wide range of clinical variables associated with aging and cardiovascular disease to determine whether they are associated with mutation status independent of chronologic age. Clinically, aging can be operationalized using geriatric assessment, which entails a comprehensive multi-dimensional assessment of the health of an older adult, including measures of comorbidity, polypharmacy, functional status, cognition, depression, falls, social activities and social support. Given that aging is heterogeneous, geriatric assessment allows greater specificity for aging than chronological age alone.

Condition or Disease Intervention/Treatment Phase
  • Other: Cognitive Assessment
  • Other: Activities of Daily Living Questionnaire
  • Other: Instrumental Activities of Daily Living, subscale of the OARS
  • Other: Karnofsky Self-reported Performance Rating Scale
  • Other: Number of Falls
  • Other: Physical Health Section, subscale of the OARS
  • Other: MOS Social Activity Survey
  • Other: Unintentional Weight Loss
  • Genetic: Peripheral Blood Draw
  • Genetic: Buccal Swab
  • Other: Heart Health and Smoking History from BRFSS questionnaire
  • Other: Gait Speed
  • Other: Grip Strength
  • Other: Height and Weight measurements
  • Other: Blood pressure measurement
  • Procedure: Optional bone marrow biopsy
  • Procedure: Blood draw for trauma measurements

Study Design

Study Type:
Observational
Anticipated Enrollment :
2000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Aging, Geriatric Syndromes and Clonal Hematopoiesis
Actual Study Start Date :
Mar 10, 2016
Anticipated Primary Completion Date :
Apr 30, 2030
Anticipated Study Completion Date :
Apr 30, 2030

Arms and Interventions

Arm Intervention/Treatment
Arm A: Clonal hematopoiesis

Complete several self-administered health assessments at baseline and every 6 months until death. Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death. Peripheral blood draw will occur at baseline and no more than every 6 months until death. Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death May be approached about optional bone marrow biopsy

Other: Cognitive Assessment
-Baseline and no more frequently than every 6 months until death

Other: Activities of Daily Living Questionnaire
10 items about daily functional status Baseline and no more frequently than every 6 months until death

Other: Instrumental Activities of Daily Living, subscale of the OARS
7 items about daily functional status Baseline and no more frequently than every 6 months until death

Other: Karnofsky Self-reported Performance Rating Scale
1 item about daily functional status Baseline and no more frequently than every 6 months until death

Other: Number of Falls
1 item about daily functional status Baseline and no more frequently than every 6 months until death

Other: Physical Health Section, subscale of the OARS
13 items about comorbidity Baseline and no more frequently than every 6 months until death

Other: MOS Social Activity Survey
4 items about social activity Baseline and no more frequently than every 6 months until death

Other: Unintentional Weight Loss
2 items about nutrition Baseline and no more frequently than every 6 months until death

Genetic: Peripheral Blood Draw
-Baseline and no more frequently than every 6 months until death

Genetic: Buccal Swab
Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush) Baseline and no more frequently than every 6 months until death

Other: Heart Health and Smoking History from BRFSS questionnaire
7 items about heart health and smoking history Baseline and no more frequently than every 6 months until death

Other: Gait Speed
Research coordinator will test gait speed Baseline and no more frequently than every 6 months until death

Other: Grip Strength
Research coordinator will test grip strength Baseline and no more frequently than every 6 months until death

Other: Height and Weight measurements
-Baseline and no more frequently than every 6 months until death

Other: Blood pressure measurement
-Baseline and no more frequently than every 6 months until death

Procedure: Optional bone marrow biopsy
-1 optional bone marrow biopsy

Arm B: No clonal hematopoiesis

Complete several self-administered health assessments at baseline and every 6 months until death. Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death. Peripheral blood draw will occur at baseline and no more than every 6 months until death. Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death May be approached about optional bone marrow biopsy

Other: Cognitive Assessment
-Baseline and no more frequently than every 6 months until death

Other: Activities of Daily Living Questionnaire
10 items about daily functional status Baseline and no more frequently than every 6 months until death

Other: Instrumental Activities of Daily Living, subscale of the OARS
7 items about daily functional status Baseline and no more frequently than every 6 months until death

Other: Karnofsky Self-reported Performance Rating Scale
1 item about daily functional status Baseline and no more frequently than every 6 months until death

Other: Number of Falls
1 item about daily functional status Baseline and no more frequently than every 6 months until death

Other: Physical Health Section, subscale of the OARS
13 items about comorbidity Baseline and no more frequently than every 6 months until death

Other: MOS Social Activity Survey
4 items about social activity Baseline and no more frequently than every 6 months until death

Other: Unintentional Weight Loss
2 items about nutrition Baseline and no more frequently than every 6 months until death

Genetic: Peripheral Blood Draw
-Baseline and no more frequently than every 6 months until death

Genetic: Buccal Swab
Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush) Baseline and no more frequently than every 6 months until death

Other: Heart Health and Smoking History from BRFSS questionnaire
7 items about heart health and smoking history Baseline and no more frequently than every 6 months until death

Other: Gait Speed
Research coordinator will test gait speed Baseline and no more frequently than every 6 months until death

Other: Grip Strength
Research coordinator will test grip strength Baseline and no more frequently than every 6 months until death

Other: Height and Weight measurements
-Baseline and no more frequently than every 6 months until death

Other: Blood pressure measurement
-Baseline and no more frequently than every 6 months until death

Procedure: Optional bone marrow biopsy
-1 optional bone marrow biopsy

Arm C: No clonal hematopoiesis & no follow-up

Complete several self-administered health assessments at baseline with no further follow-up Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline with no further follow-up Peripheral blood draw will occur at baseline with no further follow-up Buccal swabs will occur at baseline with no further follow-up

Other: Cognitive Assessment
-Baseline and no more frequently than every 6 months until death

Other: Activities of Daily Living Questionnaire
10 items about daily functional status Baseline and no more frequently than every 6 months until death

Other: Instrumental Activities of Daily Living, subscale of the OARS
7 items about daily functional status Baseline and no more frequently than every 6 months until death

Other: Karnofsky Self-reported Performance Rating Scale
1 item about daily functional status Baseline and no more frequently than every 6 months until death

Other: Number of Falls
1 item about daily functional status Baseline and no more frequently than every 6 months until death

Other: Physical Health Section, subscale of the OARS
13 items about comorbidity Baseline and no more frequently than every 6 months until death

Other: MOS Social Activity Survey
4 items about social activity Baseline and no more frequently than every 6 months until death

Other: Unintentional Weight Loss
2 items about nutrition Baseline and no more frequently than every 6 months until death

Genetic: Peripheral Blood Draw
-Baseline and no more frequently than every 6 months until death

Genetic: Buccal Swab
Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush) Baseline and no more frequently than every 6 months until death

Other: Heart Health and Smoking History from BRFSS questionnaire
7 items about heart health and smoking history Baseline and no more frequently than every 6 months until death

Other: Gait Speed
Research coordinator will test gait speed Baseline and no more frequently than every 6 months until death

Other: Grip Strength
Research coordinator will test grip strength Baseline and no more frequently than every 6 months until death

Other: Height and Weight measurements
-Baseline and no more frequently than every 6 months until death

Other: Blood pressure measurement
-Baseline and no more frequently than every 6 months until death

Arm D: Hip replacement

Complete several self-administered health assessments at baseline and every 6 months until death. Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death. Participants with or without clonal hematopoiesis who are undergoing hip replacement Peripheral blood draw will occur at baseline and no more than every 6 months until death. Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death May be approached about optional bone marrow biopsy

Arm E: Trauma

-Blood sample at the time of admission with initial bloodwork. For inpatient participants, weekly follow-up samples will be drawn with morning phlebotomy. A follow-up sample collection will occur 4-7 weeks after discharge.

Procedure: Blood draw for trauma measurements
-For Arm E only

Outcome Measures

Primary Outcome Measures

  1. Background mutation rate in hematopoietic stem cells from older adults regardless of a prior cancer diagnosis as measured by the number and frequency of hematopoietic-specific mutations [Estimated to be 10 years]

    -The investigators will sequence the coding region of some or all of the genes in an individual's blood cells and compare results to their matched mouth cells to define hematopoietic-specific mutations. The number of hematopoietic-specific mutations per individual and the frequency of individuals with mutations will be measured.

  2. Presence or absence of geriatric syndromes as measured by hematopoietic stem cell mutations [Estimated to be 10 years]

    -The presence or absence of geriatric syndromes will be correlated with the mutation status of individuals.

  3. Determine the natural history of mutations in older adults with clonal hematopoiesis as measured by risk to develop blood cancer/geriatric syndrome/illness/cardiovascular disease [Estimated to be 10 years]

    -Individuals with mutations will be followed longitudinally to monitor the fraction of hematopoietic cells with mutations, the functional consequences of mutations in their blood cells, and the risk of developing a blood cancer, geriatric syndrome, cardiovascular disease, or other illness.

  4. Presence or absence of cardiovascular disease as measured by hematopoietic stem call mutations [Estimated to be 10 years]

  5. Determine whether expansion of clonal hematopoiesis (CH) occurs following acute trauma [Estimated to be 10 years]

    -Measures change in variant allele fraction

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • At least 50 years of age.

  • Able to understand written and spoken English.

  • Able to understand and willing to sign an IRB-approved written informed consent document (or that of a legally authorized representative, if applicable for the trauma cohort)

Exclusion Criteria:
  • Inability or unwillingness to complete health questionnaire.

  • History of a recent (<30 days) acute viral illness.

  • Current cancer diagnosis and currently receiving chemotherapy or undergoing radiation therapy. A prior history of cancer is allowed if the participant completed therapy > 1 year prior to enrollment; participants with a prior diagnosis of cancer will be asked to sign a release of information for the research team to obtain records regarding their prior cancer treatment.

  • Current use of drugs that cause DNA damage (e.g. Cytoxan, azathioprine, etc.) for the treatment of a non-malignant disease.

  • Vulnerable populations (e.g. prisoners).

  • Known infection with Hepatitis B or C, HTLV, or HIV.

  • Additional exclusion for optional bone marrow aspirate/biopsy substudy:

  • Use of medications for anticoagulation or "blood thinning" including warfarin, low molecular weight heparins (enoxaparin, daltaparin) or direct-acting oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban or betrixaban)

  • allergy to lidocaine or other local anesthetics.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Washington University School of Medicine Saint Louis Missouri United States 63110

Sponsors and Collaborators

  • Washington University School of Medicine
  • Edward P. Evans Foundation

Investigators

  • Principal Investigator: Meagan Jacoby, M.D., Washington University School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT02604563
Other Study ID Numbers:
  • 201511019
First Posted:
Nov 13, 2015
Last Update Posted:
Apr 19, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2022